Opus Genetics is trading 5.01% higher at $4.60, with no fresh company-specific announcement or clearly reported catalyst identified for the October 7 move.
- Its investor-relations page lists a September 9 release reporting positive OPGx-BEST1 data and FDA discussions; October presentations include results presented at EURETINA.
- The gain runs against weak biotech and broader-market context, which does not clearly explain the rise.
- Trading activity was about 2.54 million shares versus a reported 2 million average; the quote source’s price differs from the supplied price context.